Canada-based Cipher Pharmaceuticals Inc. has acquired exclusive Canadian marketing and selling rights to Synergy Pharmaceuticals Inc.'s constipation treatment Trulance for an upfront payment of $5.0 million.
Synergy will also receive certain milestone payment and royalties on future sales of the drug in Canada. The New York-based biotechnology company will manufacture and supply the finished product to Cipher.
Trulance is approved by the U.S. Food and Drug Administration to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation.
